DH

Definitive Healthcare Corp
NASDAQHEALTHCAREHEALTH INFORMATION SERVICES

Key Statistics

Market Cap
$112.08M
P/E Ratio
EPS
$-1.62
Beta
1.40
52W High
$4.35
52W Low
$0.61
50-Day MA
$0.76
200-Day MA
$1.38
Dividend Yield
Profit Margin
-72.30%
Forward P/E
5.52
PEG Ratio

About Definitive Healthcare Corp

Definitive Healthcare Corp (DH) is a leading provider of comprehensive data and analytics solutions designed specifically for the healthcare industry, catering to a diverse clientele that includes pharmaceutical companies, payers, and healthcare providers. By harnessing extensive datasets and cutting-edge real-time analytics, Definitive Healthcare enhances operational efficiencies and delivers critical strategic insights, ultimately improving patient outcomes. With a strong commitment to innovation, the company is well-positioned to capitalize on the growing demand for sophisticated healthcare analytics, thereby establishing itself as a pivotal player in the transformation of healthcare delivery.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$232.70M
Gross Profit (TTM)$194.92M
EBITDA$35.33M
Operating Margin-8.55%
Return on Equity-78.40%
Return on Assets-1.94%
Revenue/Share (TTM)$2.23
Book Value$1.36
Price-to-Book0.78
Price-to-Sales (TTM)0.48
EV/Revenue0.583
EV/EBITDA46.69
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-9.10%
Shares Outstanding$106.75M
Float$37.28M
% Insiders3.74%
% Institutions83.55%

Historical Volatility

HV 10-Day
108.44%
HV 20-Day
93.18%
HV 30-Day
82.53%
HV 60-Day
92.63%
HV Rank
74.2%

Volatility is currently expanding

Analyst Ratings

Consensus ($1.70 target)
1
Buy
5
Hold
2
Strong Sell

Latest News

Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International

FRAMINGHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- The special committee (the “Special Committee”) of the Board of Directors of Definitive Healthcare Corp. (the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that it has received a non-binding indication of interest (the “Proposal”), dated as of September 1, 2026, from Advent International, L.P., on behalf of certain of its managed funds (collectively, “Advent”), to acquire all of the outstanding shares of the Company's Class A common stock (the “Class A Common Stock”) and all of the outstanding limited liability company interests of AIDH TopCo, LLC (the “Definitive OpCo Units”), in each case, that are not already owned by Advent or Jason Krantz, the Company's founder and Executive Chairman, for an all-cash purchase price of $1.02 per share of Class A common stock, and an equivalent amount per Definitive OpCo Unit.

GlobeNewsWire9/2/2026Neutral
Definitive Healthcare Appoints Clay Ritchey as CEO

FRAMINGHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that its Board of Directors has appointed Clay Ritchey as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective September 8, 2026.

GlobeNewsWire9/2/2026Neutral
Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast

FRAMINGHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that it will report financial results for its second quarter ended June 30, 2026, on Monday, August 10, 2026 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

GlobeNewsWire8/3/2026Neutral
Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

FRAMINGHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Srinivas Attipalli of the Company, Definitive Healthcare's new SVP and Head of AI & Data - Product, an inducement award consisting of 1,063,830 time-based restricted stock units (“RSUs”), effective July 24, 2026. These awards were individually negotiated and granted as an inducement material to Mr. Attipalli's respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire7/27/2026Neutral
Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights

Latest enhancements provide deeper medical claims insights, a new integration with HubSpot®, seamless access to healthcare professional (HCP) data directly in Salesforce, and AI search capabilities Latest enhancements provide deeper medical claims insights, a new integration with HubSpot®, seamless access to healthcare professional (HCP) data directly in Salesforce, and AI search capabilities

GlobeNewsWire5/21/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DH and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026